Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Evaluate the Effectiveness and Safety of MEK Inhibitor Combined With Anlotinib in the Treatment of Patients With Advanced KRAS Mutant Non-small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase I Clinical Study to Evaluate the Effectiveness and Safety of MEK Inhibitor Combined With Anlotinib in the Treatment of Patients With Advanced KRAS Mutant Non-small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Trametinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Jun 2024 Results of an integrative analysis for the part A plus part B (33 patients), assessing the efficacy and safety of trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Apr 2024 Status changed from recruiting to completed.
    • 09 Aug 2022 Results assessing responses after receiving at least 1 cycle of combination treatment in patients with NSCLC harboring the mutation , presented at the 2022 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top